What is the appropriate dose of intravenous immunoglobulin (IVIG) for chronic inflammatory demyelinating polyneuropathy (CIDP)?

IVIG Dosing in CIDP

For chronic inflammatory demyelinating polyneuropathy (CIDP), the standard IVIG dose is 2 g/kg as an induction dose, followed by maintenance doses of 0.4-1.0 g/kg every 3-4 weeks, with individual titration based on clinical response.

Initial (Induction) Dosing

The induction phase uses 2 g/kg total dose, typically divided over 2-5 consecutive days:

• Most commonly: 0.4 g/kg/day for 5 days 1
• Alternative: 1 g/kg/day for 2 days 1

This loading dose establishes therapeutic IgG levels and is supported by multiple clinical trials 1, 2.

Maintenance Dosing

After induction, maintenance therapy requires individualization but follows these principles:

Standard maintenance range: 0.4-1.0 g/kg every 3-4 weeks 1, 2, 3

• Most patients stabilize on ≤0.6 g/kg every 4 weeks 4
• The ProCID trial demonstrated safety and efficacy across 0.5,1.0, and 2.0 g/kg maintenance doses 1
• Dosing intervals typically range from 14-35 days based on individual response 2

Dose Titration Strategy

Start with 1.0 g/kg every 3-4 weeks after induction, then:

1. If stable improvement: Attempt gradual dose reduction by 10-20% every 3-6 months
2. If inadequate response: Increase dose incrementally up to 2.0 g/kg every 3 weeks before considering treatment failure
3. If deterioration occurs: Return to previous effective dose

The goal is to find the minimum effective dose that maintains clinical stability 3, 4.

Frequency Considerations

More frequent lower dosing (e.g., half-dose at half-interval) does not improve efficacy compared to standard interval dosing and offers no advantage in side effect profile 2. Standard 3-4 week intervals are therefore preferred for practical and cost-effectiveness reasons.

Refractory Cases

For patients with severe CIDP unresponsive to standard dosing:

High-dose IVIG (2.0-3.0 g/kg every 3 weeks) may be considered 5, 6:

• One case report showed benefit with 3 g/kg monthly (0.6 g/kg/day × 5 days) 6
• However, patients requiring very high doses (≥2 g/kg every 3 weeks) typically have greater baseline disability, concurrent autoimmune disease, worse outcomes, and longer time to improvement 5
• Critical caveat: Before escalating beyond 2 g/kg every 3 weeks, strongly consider switching to alternative therapies (corticosteroids, plasma exchange, rituximab, or newer agents) rather than continued dose escalation 5, 7

Infusion Rate

Initial rate: 0.01 mL/kg/min (0.5 mg/kg/min) Maximum rate: 0.10 mL/kg/min (5 mg/kg/min) if tolerated 8

Most patients (94.4%) tolerate maximal infusion rates of 0.12 mL/kg/min without premedication 1.

Safety Monitoring

Thromboembolic risk increases with:

• Concurrent autoimmune disease 5
• Higher doses
• Advanced age, immobility, cardiovascular risk factors 8

Ensure adequate hydration and use minimum effective doses in at-risk patients 8.

Treatment Duration and Withdrawal

• Mean treatment duration in clinical practice: 64 months (range 3-152 months) 4
• Periodic wean attempts are appropriate after sustained stability (typically ≥12 months)
• Successful complete withdrawal is possible in a subset of patients 4
• If clinical deterioration occurs during weaning, promptly return to previous effective dose

Key Pitfalls to Avoid

1. Do not automatically escalate to very high doses (>2 g/kg every 3 weeks) without first reconsidering the diagnosis and trying alternative immunotherapies 5, 7
2. Do not use more frequent dosing intervals expecting better efficacy—this is not supported by evidence 2
3. Do not continue indefinitely without attempting dose reduction in stable patients 4
4. Reconsider the diagnosis if there is lack of response to standard IVIG dosing 7